Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Amarin Corporation plcNASDAQ: AMRN

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $25.56M rose 51.3% year over year, ahead of the -27.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 4.3% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.

Context

  • Cost of revenue amounted to 43.4% of revenue in FY2025, down 21.0 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +51.3% holds above the trailing-twelve-month pace of -27.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.56M-4.3% QoQ
Last fiscal yearDec 2025
$92.78M-37.0% YoY
LTMMar 2026
$102.11M-27.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+51.3%——
1 year-37.0%——
3-year CAGR-9.9%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
92.78M USD
Year-over-year change
-37.0%
4-year CAGR
-6.5%

Cost of Revenue vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.2% is the lowest of 4, against a peer median of +67.1%.
  • Cost of revenue amounts to 47.5% of revenue for AMRN, versus a peer median of 30.2%.
AMRN Competitors
Cost of Revenue for AMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$102.11M USD-27.2%-9.9%47.5%
ALTAltimmune, Inc.LTM Mar 2026$14.98M USD——41619.4%
DBVTDBV Technologies S.A.LTM Mar 2026$13.12M USD+215.9%-4.5%—
CLLSCellectis S.A.LTM Mar 2026$12.33M USD+39.3%+4.9%18.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.33M USD——7522.6%
KRROKorro Bio, Inc.LTM Mar 2026$1.03M USD——26.8%
ENGNenGene Holdings Inc.LTM Apr 2026$369K USD———
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$284K USD+67.1%+24.6%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
Peer median (excluding AMRN) —+67.1%+0.2%30.2%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue583.19M369.19M306.91M228.61M213.65M
Cost of Revenue121.33M126.71M141.37M147.23M92.78M
Gross Profit461.86M242.48M165.54M81.38M120.87M
Gross Margin79.2%65.7%53.9%35.6%56.6%
Research & Development29.31M30.41M22.22M20.87M19.81M
Selling, General & Admin408.33M304.42M199.94M152.31M115M
Operating Expenses451.36M348.35M222.16M173.18M134.81M
Depreciation & Amortization2.86M3.1M2.97M3.01M3.03M
EBITDA14.28M(100.69M)(50.7M)(74.18M)(33.01M)
EBITDA Margin2.4%-27.3%-16.5%-32.4%-15.5%
Operating Income10.5M(105.87M)(56.62M)(91.8M)(13.94M)
Operating Margin1.8%-28.7%-18.4%-40.2%-6.5%
Interest Income1.22M2.82M11.86M13.4M10.85M
Interest Expense129K15K8K7K7K
Other Income / Expenses789K2.06M2.95M14.6M(22.11M)
Income Before Tax11.29M(103.81M)(53.67M)(77.2M)(36.05M)
Pre-Tax Margin1.9%-28.1%-17.5%-33.8%-16.9%
Income Tax Expense3.56M2M5.44M4.98M2.75M
Net Income7.73M(105.8M)(59.11M)(82.18M)(38.8M)
Net Margin1.3%-28.7%-19.3%-35.9%-18.2%
EPS (Basic)0.39(5.20)(3.00)(4.00)(1.80)
EPS (Diluted)0.38(5.20)(3.00)(4.00)(1.80)
Weighted Avg Shares19.8M20.06M19.7M20.55M20.75M
Weighted Avg Shares (Diluted)20.12M20.06M20.38M20.55M20.75M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.